福多司坦治疗慢性阻塞性肺疾病伴肺纤维化患者的临床效果

Clinical effect of fudosteine in the treatment of patients with chronic obstructive pulmonary disease with pulmonary fibrosis

目的分析福多司坦治疗慢性阻塞性肺疾病(COPD)伴肺纤维化患者的临床效果。方法选择2019年1月至2020年1月我院收治的60例COPD伴肺纤维化患者,根据治疗方法的不同将其分为对照组和观察组,各30例。对照组采用乙酰半胱氨酸治疗,观察组在对照组基础上使用福多司坦治疗。比较两组治疗前及治疗6、9个月后的肺功能、肺纤维化指标及血清学指标。结果治疗6、9个月后,观察组的第1秒用力呼气容积(FEV1)、用力肺活量(FVC)高于对照组(P<0.05)。治疗6、9个月后,观察组的血清透明质酸(HA)、层粘连蛋白(LN)、白细胞介素-8(IL-8)、细胞间黏附分子-1(ICAM-1)、涎液化糖链抗原-6(KL-6)、转化生长因子β1(TGF-β1)、趋化因子CXC配体13(CXCL13)水平低于对照组(P<0.05)。结论福多司坦治疗COPD伴肺纤维化患者能够改善肺功能,缓解肺纤维化,调节血清因子水平,值得推广应用。

Objective To analyze the clinical effect of fudosteine in the treatment of chronic obstructive pulmonary disease(COPD)with pulmonary fibrosis.Methods Sixty patients with COPD and pulmonary fibrosis admitted in our hospital from January 2019 to January 2020 were selected and divided into control group and observation group according to different treatment methods,with 30 cases in each group.The control group was treated with acetylcysteine,and the observation group was treated with fudosteine on the basis of the control group.The pulmonary function,pulmonary fibrosis indexes and serological indexes were compared between the two groups before treatment and after 6 and 9 months of treatment.Results After 6 and 9 months of treatment,the forced expiratory volume in one second(FEV1)and forced vital capacity(FVC)in the observation group were higher than those in the control group(P<0.05).After 6 and 9 months of treatment,the levels of serum hyaluronic acid(HA),laminin(LN),interleukin-8(IL-8),intercellular cell adhesion molecule-1(ICAM-1),krebs von den lungen-6(KL-6),transforming growth factor-β1(TGF-β1)and chemokine CXC ligand 13(CXCL13)in the observation group were lower than those in the control group(P<0.05).Conclusion Fordosteine in the treatment of COPD patients with pulmonary fibrosis can strengthen pulmonary function,relieve pulmonary fibrosis,and regulate serum factor levels,which is worth of promotion and application.